Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Oxaprozin Action Pathway
Homo sapiens
Drug Action Pathway
Oxaprozin (also named Daypro, Dayrun) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to relieve pain (analgesic) and reduce fever (antipyretic). Oxaprozin is also a type of ophthalmic anti-inflammatory medicines which may be used to help prevent eye constrict for pupil during surgery. Oxaprozin can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Since prostaglandin is the messenger molecules in the process of inflammation; hence, inhibition of prostaglandin synthesis can reduce the pain and inflammation.
References
Oxaprozin Pathway References
Botting, R., & Botting, J. Cyclooxygenases. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology. (2004) p.279-283. Berlin, Germany: Springer.
Breyer, R.M., & Breyer, M.D. Prostanoids. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology. (2004) p. 752-757. Berlin, Germany: Springer.
Daypro. (2009). e-CPS (online version of Compendium of Pharmaceuticals and Specialties). Retrieved August 15, 2009.
Lopes-de-Araujo J, Neves AR, Gouveia VM, Moura CC, Nunes C, Reis S: Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects. Pharm Res. 2016 Feb;33(2):301-14. doi: 10.1007/s11095-015-1788-x. Epub 2015 Sep 9.
Pubmed: 26350105
Bozic BD, Rogan JR, Poleti DD, Trisovic NP, Bozic BD, Uscumlic GS: Synthesis, characterization and antiproliferative activity of transition metal complexes with 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid (oxaprozin). Chem Pharm Bull (Tokyo). 2012;60(7):865-9. doi: 10.1248/cpb.c12-00185.
Pubmed: 22790819
Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998 Mar 30;104(3A):2S-8S; discussion 21S-22S. doi: 10.1016/s0002-9343(97)00203-9.
Pubmed: 9572314
Maestrelli F, Cirri M, Mennini N, Zerrouk N, Mura P: Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components. Eur J Pharm Biopharm. 2011 Aug;78(3):385-93. doi: 10.1016/j.ejpb.2011.03.012. Epub 2011 Mar 23.
Pubmed: 21439375
Peesa JP, Atmakuri LR, Yalavarthi PR, Mandava Venkata BR, Rasheed A, Pachava V: Oxaprozin prodrug as safer nonsteroidal anti-inflammatory drug: Synthesis and pharmacological evaluation. Arch Pharm (Weinheim). 2018 Feb;351(2). doi: 10.1002/ardp.201700256. Epub 2017 Dec 28.
Pubmed: 29283449
Arachidonic Acid Metabolism References
Lehninger, A.L. Lehninger principles of biochemistry (4th ed.) (2005). New York: W.H Freeman.
Vance, D.E., and Vance, J.E. Biochemistry of lipids, lipoproteins, and membranes (4th ed.) (2002) Amsterdam; Boston: Elsevier.
Salway, J.G. Metabolism at a glance (3rd ed.) (2004). Alden, Mass.: Blackwell Pub.
Kroetz DL, Zeldin DC: Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 2002 Jun;13(3):273-83.
Pubmed: 12045397
Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001 Sep 28;276(39):36059-62. doi: 10.1074/jbc.R100030200. Epub 2001 Jul 12.
Pubmed: 11451964
Ondrey FG: Arachidonic acid metabolism: a primer for head and neck surgeons. Head Neck. 1998 Jul;20(4):334-49.
Pubmed: 9588707
Sigal E: The molecular biology of mammalian arachidonic acid metabolism. Am J Physiol. 1991 Feb;260(2 Pt 1):L13-28. doi: 10.1152/ajplung.1991.260.2.L13.
Pubmed: 1899973
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings